Wedoany.com Report-Dec.17, An affiliate of U.S.-based private investment firm SK Capital Partners has committed capital to Swixx BioPharma, aimed at facilitating the company's continued development and broader geographic reach.

The company's mission is to provide access to essential medications in hard-to-reach and underserved regions.

The transaction assigns Swixx a valuation exceeding €1.5 billion ($1.76 billion).

Swixx functions as a specialized platform assisting pharmaceutical manufacturers in commercializing products in regions where direct presence is limited or absent. Its core objective centers on ensuring availability of vital treatments in challenging and less-served areas.

The company's operations cover Greece, Central and Eastern Europe, Eurasia, select Commonwealth of Independent States nations, Latin America, and the Middle East.

Revenue projections for Swixx indicate levels surpassing €1.3 billion in 2026.

Co-founders Stuart Swanson and Petr Němec, together with CEO Jean-Michel Lespinasse and CFO Petr Pipal, will retain substantial equity positions following the investment. Existing shareholders HBM Healthcare Investments and Mérieux Equity Partners will continue their involvement.

Lespinasse commented: "This partnership marks a pivotal moment for Swixx, bringing both additional capital and expertise to drive our growth. We remain committed to expanding our role as the trusted partner for leading global biopharmaceutical companies, delivering sustainable outsourcing solutions in complex and emerging markets — and ultimately improving access and outcomes for patients."

Financial advisory services for SK Capital were provided exclusively by Rothschild & Co, with legal guidance from Bär & Karrer and Kirkland & Ellis. KPMG conducted due diligence across tax, financial, compliance, and IT aspects, while ClearView Healthcare Partners assessed commercial elements.

Debt financing for the arrangement was arranged through Ares Credit funds.

On behalf of Swixx, Jefferies led financial advisory efforts, supported by Centerview Partners. Legal counsel came from Walder Wyss. EY handled financial, tax, compliance, and legal vendor due diligence, with BCG contributing to commercial vendor assessments.

As of December 31, 2024, SK Capital oversees assets approaching $10 billion.

This collaboration equips Swixx with resources to scale its platform, enhancing service capabilities for partner pharmaceutical entities in diverse international settings.

By maintaining founder and management involvement, the structure ensures continuity in strategic direction and operational expertise.

The partnership underscores confidence in Swixx's model of bridging gaps in medication distribution, particularly where infrastructure or market dynamics present obstacles.

Expanded capital supports investments in local networks, regulatory navigation, and supply chain optimization across covered territories.

Swixx's multi-regional presence facilitates tailored approaches to each market's unique requirements, from regulatory approvals to distribution logistics.

The transaction highlights growing interest in specialized commercialization partners that enable efficient entry into non-core geographies for global biopharma firms.

Retained institutional investors provide ongoing stability and alignment with long-term goals.

Professional advisory teams from leading firms ensured comprehensive evaluation across all facets of the deal.

Financing arrangements reflect structured support tailored to growth-oriented healthcare investments.

Overall, the investment positions Swixx to strengthen its contributions toward broader therapeutic availability, leveraging combined expertise to address unmet needs in varied global contexts.